Jun 29, 2026
New England Journal of Medicine Retracts Amgen's Tavneos Clinical Trial Amid Data Manipulation Allegations
The New England Journal of Medicine retracted the main clinical trial used to approve Amgen's $500 million drug Tavneos, following allegations of data manipulation. The European Medicines Agency had previously recommended revoking the drug's approval over data integrity concerns.
1 source
00